Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations

ConclusionsStandard parametric models fitted to the initial ATLANTIC DCO generally underestimated longer-term OS, compared with the later DCO. Cure, parametric mixture and response-based landmark models predicted that larger proportions of patients with metastatic non-small cell lung cancer receiving IO treatments may experience long-term survival, which was more in keeping with the observed data. Further research using more mature OS data for IO treatments is needed.
Source: PharmacoEconomics - Category: Health Management Source Type: research

Related Links:

Worldwide, especially in China, lung cancer accounts to a major cause of mortality related to cancer. Treatment decisions mainly depend on oncogenic driver mutations, which offer novel therapeutic targets for anticancer therapy. However, studies of genomic profiling of driver gene mutations in mainland China are rare. Hence, this is an extensive study of these mutations in Non-small-cell lung cancer (NSCLC) Chinese patients. Comparison of driver gene mutations of lung adenocarcinoma with other races showed that the mutational frequencies were similar within the different East Asian populations, while there were differences...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
In this study, we constructed bioconjugates of targeting immune checkpoint B7 −H3 antibody and chlorin e6 to treat non-small cell lung cancer under the guidance of spectroscopic photoacoustic and fluorescence imaging.... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
Authors: Weng X, Luo S, Lin S, Zhong L, Li M, Xin R, Huang P, Xu X Abstract To evaluate the cost-utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic non-small cell lung cancer (NSCLC) from the US health care system perspective. A Markov model was developed to compare the life-time cost and effectiveness of pembrolizumab versus chemotherapy for untreated metastatic NSCLC, based on the clinical data derived from phase III randomized controlled trial (KEYNOTE-042, ClinicalTrials.gov, NCT02220894). Weibull distribution was fitted to simulate the parametric survival functions. Drug cost...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, whom received apatinib (250mg or 500mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy as second- or more line systemic therapy until disease progression or unacceptable toxicity occurred. The objective response rate (ORR), disease control rat...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
Publication date: Available online 15 October 2019Source: The Lancet Respiratory MedicineAuthor(s): Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang WuSummaryBackgroundEnsartinib is a potent new-generation ALK inhibitor with high activity against a broad range of known crizotinib-resistant ALK mutations and CNS metastases. We aimed to assess the efficacy and safety of ensartinib in ALK-positive patients with non-small-cell lung cancer (NSCLC), i...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
ConclusionsThe models with semantic and texture features provided cross-validated AUCs of 0.85 –0.88 for classification of benign versus cancerous nodules, showing potential in aiding the management of patients.Key Points• Pretest probability of cancer can aid and direct the physician in the diagnosis and management of pulmonary nodules in a cost-effective way.• Semantic features (qualitative features reported by radiologists to characterize lung lesions) and radiomic (e.g., texture) features can be extracted from CT images.• Input of these variables into a model can generate a pretest likelihood of ca...
Source: European Radiology - Category: Radiology Source Type: research
Noninvasive prognostic biomarkers are needed for advanced non-small cell lung cancer (NSCLC) patients with different histological types to identify cases with poor survival. Here, we investigated the prognosti...
Source: Journal of Translational Medicine - Category: Research Authors: Tags: Research Source Type: research
This study explored the effect of ginsenoside Rg3 on DNA repair and VRK1/P53BP1 signaling pathway. Ginsenoside Rg3 treatment significantly decreased the incidence and invasionin a mouse model of lung cancer induced by urethane. The results of cell survival assay and single cell gel electrophoresis showed that ginsenoside Rg3 protected lung adenocarcinoma cells from DNA damage as well as inhibited the proliferation of tumor cells. Ginsenoside Rg3 increased the mRNA and protein expression of VRK1 in NSCLC cells as measured by RT-qPCR and western blot, respectively. These findings suggests that ginsenoside Rg3 regulates VRK1 ...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
The Pharmacogenomics Journal, Published online: 17 October 2019; doi:10.1038/s41397-019-0110-4Dissecting the m6A methylation affection on afatinib resistance in non-small cell lung cancer
Source: The Pharmacogenomics Journal - Category: Drugs & Pharmacology Authors: Source Type: research
Condition:   Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Interventions:   Drug: TAK-788;   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Carboplatin Sponsor:   Millennium Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Health Management | Lung Cancer | Non-Small Cell Lung Cancer | Study